E-ISSN 2146-9369 | ISSN 2146-3158
 
2024, Vol: 14, Issue: 1
14 / 1Current Issue ArchiveAims and ScopeAbstracting & IndexingMost Accessed ArticlesMost Downloaded ArticlesMost Cited Articles

Research Article 


Clinical and microbiological impact of inhaled tobramycin treatment on cystic fibrosis patients with Pseudomonas aeruginosa

Francesca Dickhaus, Mutasim Abu Hasan, Elizabeth Tremblay, Kenneth Klinker, Kenneth Rand, Stacy G. Beal.

Abstract
Objective: Patients ' with cystic fibrosis respiratory systems become colonized with pathogens as early as the first year of life. Some organisms are associated with a decline in pulmonary function and shortened survival, such as a mucoid strain of Pseudomonas aeruginosa (PA).<br>Methods: We conducted a four year retrospective chart review study examining 158 pediatric and adult cystic fibrosis patients treated at an academic, tertiary care institution to compare patients treated by different antimicrobial regimens.<br>Results: A higher proportion of mucoid PA study patients received alternate-monthly tobramycin therapy (83.3%), compared to those with non-mucoid PA (62.5%); although a large percentage of patients who had never had a mucoid PA infection were also receiving alternate-monthly tobramycin. Patients who had a mucoid PA infection had more hospitalizations and for longer periods of time than patients who had a non-mucoid PA infection; both mucoid and non-mucoid PA patients were hospitalized more often than patients who had never had a PA infection. We additionally found patients with mucoid PA infections to have strains that were either resistant or had intermediate resistance to tobramycin. Similar trends in resistance were not seen in patients who only received intermittent treatments with tobramycin.<br>Conclusions Our findings on increased rates of infection with both Aspergillus (in the alternate-monthly inhaled tobramycin group) and NTM (in the overall patient population) comparative to international averages were also interesting, and open the doors to future research regarding CF patients with these infections. J Microbiol Infect Dis 2017; 7(4):178-185

Key words: Cystic fibrosis, Pseudomonas, Tobramycin


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Francesca Dickhaus
Articles by Mutasim Abu Hasan
Articles by Elizabeth Tremblay
Articles by Kenneth Klinker
Articles by Kenneth Rand
Articles by Stacy G. Beal
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Francesca Dickhaus, Mutasim Abu Hasan, Elizabeth Tremblay, Kenneth Klinker, Kenneth Rand, Stacy G. Beal. Clinical and microbiological impact of inhaled tobramycin treatment on cystic fibrosis patients with Pseudomonas aeruginosa. J Microbiol Infect Dis. 2017; 7(4): 178-185 . doi:10.5799/jmid.368802

Web Style

Francesca Dickhaus, Mutasim Abu Hasan, Elizabeth Tremblay, Kenneth Klinker, Kenneth Rand, Stacy G. Beal. Clinical and microbiological impact of inhaled tobramycin treatment on cystic fibrosis patients with Pseudomonas aeruginosa. https://www.jmidonline.org/?mno=302657038 [Access: February 04, 2024]. doi:10.5799/jmid.368802

AMA (American Medical Association) Style

Francesca Dickhaus, Mutasim Abu Hasan, Elizabeth Tremblay, Kenneth Klinker, Kenneth Rand, Stacy G. Beal. Clinical and microbiological impact of inhaled tobramycin treatment on cystic fibrosis patients with Pseudomonas aeruginosa. J Microbiol Infect Dis. 2017; 7(4): 178-185 . doi:10.5799/jmid.368802


Vancouver/ICMJE Style

Francesca Dickhaus, Mutasim Abu Hasan, Elizabeth Tremblay, Kenneth Klinker, Kenneth Rand, Stacy G. Beal. Clinical and microbiological impact of inhaled tobramycin treatment on cystic fibrosis patients with Pseudomonas aeruginosa. J Microbiol Infect Dis. (2017), [cited February 04, 2024]; 7(4): 178-185 . doi:10.5799/jmid.368802


Harvard Style

Francesca Dickhaus, Mutasim Abu Hasan, Elizabeth Tremblay, Kenneth Klinker, Kenneth Rand, Stacy G. Beal (2017) Clinical and microbiological impact of inhaled tobramycin treatment on cystic fibrosis patients with Pseudomonas aeruginosa. J Microbiol Infect Dis, 7 (4), 178-185 . doi:10.5799/jmid.368802


Turabian Style

Francesca Dickhaus, Mutasim Abu Hasan, Elizabeth Tremblay, Kenneth Klinker, Kenneth Rand, Stacy G. Beal. 2017. Clinical and microbiological impact of inhaled tobramycin treatment on cystic fibrosis patients with Pseudomonas aeruginosa. Journal of Microbiology and Infectious Diseases, 7 (4), 178-185 . doi:10.5799/jmid.368802


Chicago Style

Francesca Dickhaus, Mutasim Abu Hasan, Elizabeth Tremblay, Kenneth Klinker, Kenneth Rand, Stacy G. Beal. "Clinical and microbiological impact of inhaled tobramycin treatment on cystic fibrosis patients with Pseudomonas aeruginosa." Journal of Microbiology and Infectious Diseases 7 (2017), 178-185 . doi:10.5799/jmid.368802


MLA (The Modern Language Association) Style

Francesca Dickhaus, Mutasim Abu Hasan, Elizabeth Tremblay, Kenneth Klinker, Kenneth Rand, Stacy G. Beal. "Clinical and microbiological impact of inhaled tobramycin treatment on cystic fibrosis patients with Pseudomonas aeruginosa." Journal of Microbiology and Infectious Diseases 7.4 (2017), 178-185 . Print. doi:10.5799/jmid.368802


APA (American Psychological Association) Style

Francesca Dickhaus, Mutasim Abu Hasan, Elizabeth Tremblay, Kenneth Klinker, Kenneth Rand, Stacy G. Beal (2017) Clinical and microbiological impact of inhaled tobramycin treatment on cystic fibrosis patients with Pseudomonas aeruginosa. Journal of Microbiology and Infectious Diseases, 7 (4), 178-185 . doi:10.5799/jmid.368802


Author LoginReviewer LoginAbout PublisherOpen Access PolicyEditorial PoliciesPeer Review PolicyPublication Ethics and Publication Malpractice StatementConflict of Interest PolicyPlagiarism PolicyProtection of Research Participants (Statement On Human And Animal Rights)Privacy PolicyCorrections, Retractions & Expressions of ConcernSelf-Archiving PoliciesDigital Archiving & Preservation PoliciesStatement of Informed ConsentAdvertising PolicyTerms of UseLicense InformationCopyright Information

About Journal of Microbiology and Infectious Diseases

Journal of Microbiology and Infectious Diseases (JMID) is an international "peer review" journal in microbiology, infectious diseases, virology, ... Read more.



For best results, please use Internet Explorer or Google Chrome.

Contact Information

All correspondence should be addressed to:

Prof. Ibrahim Eldaghayes

Editor-in-Chief

Journal of Microbiology and Infectious Diseases

Department of Microbiology and Parasitology 

Faculty of Veterinary Medicine

University of Tripoli

P.O. Box 13662, Tripoli, Libya